Humacyte (HUMA) Competitors $1.53 -0.04 (-2.55%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$1.54 +0.01 (+0.65%) As of 09/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HUMA vs. TSHA, PHAT, IOVA, PRAX, AKBA, AVBP, IMNM, KALV, AVXL, and ABUSShould you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Taysha Gene Therapies (TSHA), Phathom Pharmaceuticals (PHAT), Iovance Biotherapeutics (IOVA), Praxis Precision Medicines (PRAX), Akebia Therapeutics (AKBA), ArriVent BioPharma (AVBP), Immunome (IMNM), KalVista Pharmaceuticals (KALV), Anavex Life Sciences (AVXL), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. Humacyte vs. Its Competitors Taysha Gene Therapies Phathom Pharmaceuticals Iovance Biotherapeutics Praxis Precision Medicines Akebia Therapeutics ArriVent BioPharma Immunome KalVista Pharmaceuticals Anavex Life Sciences Arbutus Biopharma Taysha Gene Therapies (NASDAQ:TSHA) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends. Do institutionals & insiders believe in TSHA or HUMA? 77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 3.8% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 5.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is TSHA or HUMA more profitable? Humacyte has a net margin of 0.00% compared to Taysha Gene Therapies' net margin of -1,144.97%. Humacyte's return on equity of 0.00% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-1,144.97% -78.44% -44.82% Humacyte N/A N/A -78.26% Does the media prefer TSHA or HUMA? In the previous week, Humacyte had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 8 mentions for Humacyte and 7 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.95 beat Humacyte's score of 0.32 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more volatility and risk, TSHA or HUMA? Taysha Gene Therapies has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Which has stronger earnings & valuation, TSHA or HUMA? Taysha Gene Therapies has higher revenue and earnings than Humacyte. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$8.33M94.97-$89.30M-$0.34-8.53Humacyte$1.57M154.34-$148.70M-$0.45-3.40 Do analysts rate TSHA or HUMA? Taysha Gene Therapies currently has a consensus target price of $8.29, indicating a potential upside of 185.71%. Humacyte has a consensus target price of $9.75, indicating a potential upside of 537.25%. Given Humacyte's higher probable upside, analysts clearly believe Humacyte is more favorable than Taysha Gene Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Humacyte 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 SummaryTaysha Gene Therapies and Humacyte tied by winning 8 of the 16 factors compared between the two stocks. Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HUMA vs. The Competition Export to ExcelMetricHumacyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$248.64M$3.12B$5.74B$10.30BDividend YieldN/A2.37%5.89%4.62%P/E Ratio-3.4021.0376.6726.52Price / Sales154.34249.02443.4987.66Price / CashN/A45.4837.2260.63Price / Book-3.739.5613.946.31Net Income-$148.70M-$53.02M$3.29B$271.37M7 Day Performance2.00%-1.41%-0.67%0.59%1 Month Performance-15.00%2.98%3.90%6.22%1 Year Performance-71.35%9.49%86.24%28.35% Humacyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HUMAHumacyte2.8152 of 5 stars$1.53-2.5%$9.75+537.3%-70.7%$248.64M$1.57M-3.40150Analyst ForecastTSHATaysha Gene Therapies2.4427 of 5 stars$3.24-3.6%$8.29+155.7%+33.0%$883.87M$8.33M-9.53180PHATPhathom Pharmaceuticals2.3859 of 5 stars$12.43+0.7%$17.50+40.8%-40.5%$881.78M$55.25M-2.63110Positive NewsIOVAIovance Biotherapeutics4.3338 of 5 stars$2.38-4.4%$11.90+400.0%-78.7%$861.20M$164.07M-1.93500PRAXPraxis Precision Medicines2.3036 of 5 stars$40.75-13.0%$85.88+110.7%-23.7%$857.79M$8.55M-3.32110High Trading VolumeAKBAAkebia Therapeutics3.7836 of 5 stars$3.13+5.7%$6.75+115.7%+104.4%$829.89M$160.18M-18.41430Positive NewsAVBPArriVent BioPharma2.0128 of 5 stars$20.21+0.1%$39.14+93.7%-26.9%$819.90MN/A-5.0340High Trading VolumeIMNMImmunome2.2063 of 5 stars$9.40-10.6%$22.89+143.5%-41.6%$818.18M$9.04M-3.0540Positive NewsKALVKalVista Pharmaceuticals4.0028 of 5 stars$15.96+0.9%$26.29+64.7%+26.6%$803.43MN/A-4.33100Earnings ReportAVXLAnavex Life Sciences3.7649 of 5 stars$9.35-0.5%$44.00+370.6%+60.8%$803.07MN/A-16.4040Positive NewsABUSArbutus Biopharma1.9634 of 5 stars$4.09-2.6%$5.00+22.2%+8.6%$784.05M$6.17M-14.1090Positive News Related Companies and Tools Related Companies TSHA Competitors PHAT Competitors IOVA Competitors PRAX Competitors AKBA Competitors AVBP Competitors IMNM Competitors KALV Competitors AVXL Competitors ABUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HUMA) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTen Bucks, Five Minutes... Could Send You Up to $8K QUARTERLYDOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredWhy Peter Thiel Hid Gold in a VaultSilicon Valley billionaires hiding gold in vaults? Peter Thiel’s Palantir quietly diverted tens of millions...Golden Portfolio | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HUMA Stock Alerts